The Journal of dermatological treatment最新文献_第5页

Fractional microneedle radiofrequency with the application of vitamin C, E, and ferulic acid serum for neck skin rejuvenation: a prospective, double-blinded, split-neck, placebo-controlled trial. 微针射频与维生素C， E和阿魏酸血清的应用颈部皮肤年轻化：一项前瞻性，双盲，裂颈，安慰剂对照试验。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-04 DOI: 10.1080/09546634.2025.2504655

Jemin Kim, Sang Gyu Lee, Jihee Boo, Hyun Kim, Shinwon Hwang, Chaocheng Liu, Xi Yan, Patricia Brieva, Jihee Kim

{"title":"Fractional microneedle radiofrequency with the application of vitamin C, E, and ferulic acid serum for neck skin rejuvenation: a prospective, double-blinded, split-neck, placebo-controlled trial.","authors":"Jemin Kim, Sang Gyu Lee, Jihee Boo, Hyun Kim, Shinwon Hwang, Chaocheng Liu, Xi Yan, Patricia Brieva, Jihee Kim","doi":"10.1080/09546634.2025.2504655","DOIUrl":"10.1080/09546634.2025.2504655","url":null,"abstract":"Purpose: To evaluate the efficacy of fractional microneedle radiofrequency (FMR) combined with topical antioxidant serum (vitamin C, E, and ferulic acid) compared to FMR alone for neck rejuvenation.Materials and methods: This prospective, randomized, double-blind, split-neck trial included 31 participants aged 30-65 years with visible signs of neck aging. Subjects underwent two FMR treatments at 4-week intervals. Immediately post-treatment, participants applied antioxidant serum to one randomly assigned side of the neck and placebo to the contralateral side daily. Efficacy was assessed by Fitzpatrick Wrinkle and Elastosis Scale, Global Esthetic Improvement Scale (GAIS), and biophysical skin parameters. Histological analyses evaluated elastin production and markers of senescence.Results: At week 12, the antioxidant-treated neck side showed significantly greater reductions in wrinkle severity (29.9% vs. 18.0%; p < 0.001), increased elasticity (12.9% vs. 2.3%; p < 0.001), and higher GAIS improvement (87.5% vs. 14.3%). Histologically, antioxidant-treated areas exhibited increased elastin and reduced cellular senescence markers (p16 and γ-H2A.X).Conclusions: Combining FMR with topical antioxidant serum substantially enhances neck skin rejuvenation, demonstrating superior clinical and histological outcomes. This approach effectively addresses neck aging, highlighting antioxidants as valuable adjunctive therapies.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2504655"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients. 纳洛酮成功治疗哈雷-哈雷病2例报告及阿片受体拮抗剂治疗哈雷-哈雷病疗效文献综述

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-22 DOI: 10.1080/09546634.2025.2453597

Junyou Zheng, Zhimin Duan, Beilei Xu, Hao Song, Jianbing Wu, Fang Fang, Nan Sheng, Chengrang Li

{"title":"Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients.","authors":"Junyou Zheng, Zhimin Duan, Beilei Xu, Hao Song, Jianbing Wu, Fang Fang, Nan Sheng, Chengrang Li","doi":"10.1080/09546634.2025.2453597","DOIUrl":"10.1080/09546634.2025.2453597","url":null,"abstract":"Background: Hailey-Hailey disease (HHD), a genetic blistering disease, is caused by a mutation in a calcium transporter protein in the Golgi apparatus encoded by the ATP2C1 gene. Clinically, HHD is characterized by flaccid vesicles, blisters, erosions, fissures, and maceration mainly in intertriginous regions. Some patients remain refractory to conventional treatments. Previously, a series of reports have confirmed naltrexone as an effective option for those patients. However, in China, naltrexone is unavailable in some hospitals and unaffordable for some patients.Objective: To confirm naloxone as a treatment option for HHD, and assess the efficacy rate and safety of naltrexone for patients with HHD.Methods: Two patients with biopsy-proven HHD received naloxone (2 mg/d, via intravenous infusion). We followed up with the two patients, assessing the change of skin lesions and obtaining photographs. We searched the PubMed databases using the keywords 'Hailey-Hailey disease' or 'benign familial pemphigus', and 'naltrexone' or 'naloxone', and reviewed English publications of reports and analyzed the efficacy and safety of naltrexone.Results: Two patients prescribed naloxone showed completely remission in two weeks without any adverse reactions. The total remission rate of naltrexone for HHD is approximately 80%, without severe adverse effects.Conclusion: Naltrexone is effective and safe in the treatment of HHD. Naloxone, an analog of naltrexone, can also effectively and safely treat HHD, potentially offering a new therapeutic option for patients with refractory HHD.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2453597"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report. 刺猬通路抑制剂（HHI）联合放疗和免疫治疗晚期基底细胞癌1例报告

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-06 DOI: 10.1080/09546634.2025.2462783

Zhuren Ruan, Chen Zhao, Longshan Li, Xianghui Li, Zhijian Yao, Gao Wei

引用次数: 0

Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis. 使用tapinarof乳膏治疗特应性皮炎或斑块型牛皮癣患者的毛囊事件和接触性皮炎的特点和管理。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-07-02 DOI: 10.1080/09546634.2025.2517388

Linda Stein Gold, Matthew J Bruno, G Michael Lewitt, Adelaide A Hebert

{"title":"Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis.","authors":"Linda Stein Gold, Matthew J Bruno, G Michael Lewitt, Adelaide A Hebert","doi":"10.1080/09546634.2025.2517388","DOIUrl":"https://doi.org/10.1080/09546634.2025.2517388","url":null,"abstract":"Purpose: Provide insights into the incidence, pre-sentation and management of follicular events and contact dermatitis in patients with plaque psoriasis or atopic dermatitis (AD) treated with tapinarof cream 1%.Materials and methods: Key clinical trial publications for tapinarof were reviewed and augmented with the authors' opinions based on real-world clinical experience.Results: In the PSOARING and ADORING trials, discontinuation rates due to follicular events and contact dermatitis were low and most patients did not require dose modifications or treatment interruptions. In our experience, which includes the use of tapinarof in combination with other agents, tapinarof is generally well tolerated and if events of folliculitis or contact dermatitis occur, patients can be advised to temporarily discontinue application on affected sites until the event resolves, continuing application to other affected areas and body regions. Education on the correct application of tapinarof is important in the management of psoriasis and AD.Conclusions: Tapinarof is a novel topical treatment option for adults with plaque psoriasis and patients with AD, with no restrictions regarding application sites and duration of use. Follicular events and contact dermatitis associated with tapinarof treatment are generally mild and self-limiting and rarely interfere with therapy.Clinicaltrials.gov numbers: NCT05014568, NCT05032859, NCT05142774, NCT03956355, NCT03983980, NCT04053387.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2517388"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lessons from a decentralized trial in atopic dermatitis: promises and perils. 特应性皮炎分散试验的经验教训：希望与危险。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-04-03 DOI: 10.1080/09546634.2025.2480747

Zhihong Lai, Candice M Estes, Stephanie Lyke, Haq Nawaz

引用次数: 0

A year in review: new treatments and expanded indications in dermatology in 2024. 年度回顾：2024 年皮肤病学的新疗法和适应症扩展。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/09546634.2025.2456528

Lauren N McGrath, Lila G McGrath, John R Edminister

引用次数: 0

Patient and healthcare provider perspectives on treatment patterns and patient satisfaction of seborrheic dermatitis in the United States. 美国患者和医疗保健提供者对脂溢性皮炎治疗模式和患者满意度的看法。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-11 DOI: 10.1080/09546634.2025.2476576

Raj Chovatiya, Christy H Chang, Lakshi Aldredge, Candrice Heath, Moises Acevedo, David H Chu, Diane Hanna, Melissa S Seal, Matthew Zirwas

{"title":"Patient and healthcare provider perspectives on treatment patterns and patient satisfaction of seborrheic dermatitis in the United States.","authors":"Raj Chovatiya, Christy H Chang, Lakshi Aldredge, Candrice Heath, Moises Acevedo, David H Chu, Diane Hanna, Melissa S Seal, Matthew Zirwas","doi":"10.1080/09546634.2025.2476576","DOIUrl":"10.1080/09546634.2025.2476576","url":null,"abstract":"Introduction: Seborrheic dermatitis (SD) affects a large, diverse population and is associated with significant morbidity/burden.Methods: The Harris Poll conducted online surveys to understand the perceptions, preferences, and experiences regarding treatments of US patients with SD and dermatology healthcare providers (HCPs) from December 2021 to January 2022.Results: In this survey, patients using SD treatment invested on average 34 min/d treating SD with 5.9 different treatments/week (cost: ∼$650/year). HCPs underestimated duration of SD treatment (16 min/d). Most patients agreed current treatment options are too time-consuming (61%), and would be more likely to continue a regimen with fewer treatments (88%). Few patients were 'very satisfied' with treatment option affordability (19%) and prescription treatment effectiveness (25%); only 8.7% of HCPs were satisfied with prescription SD treatment options available. Most patients acknowledged SD was difficult to treat (73%) and were interested in trying new treatments (87%). HCPs expressed the need for new treatments (92%) and agreed patients would be interested in trying them (95%). Patients prioritized symptom relief over look/feel of product and regimens that could be easily incorporated into hair routines. Patients would like HCPs to consider skin tone when recommending treatments (81%) and agreed cultural background affects treatment preference (55%).Conclusions: These findings suggest a need for SD treatments that address patient concerns/frustrations with current time-intensive complex regimens, and consider diverse hair care routines/cultural backgrounds.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2476576"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angiolymphoid hyperplasia with eosinophilia responded well to dupilumab in two cases. 2例血管淋巴样增生伴嗜酸性粒细胞增多对dupilumab反应良好。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-04-14 DOI: 10.1080/09546634.2025.2485262

Yi Jiang, Yu Xiao, Yang Wang, Panpan Shang

{"title":"Angiolymphoid hyperplasia with eosinophilia responded well to dupilumab in two cases.","authors":"Yi Jiang, Yu Xiao, Yang Wang, Panpan Shang","doi":"10.1080/09546634.2025.2485262","DOIUrl":"https://doi.org/10.1080/09546634.2025.2485262","url":null,"abstract":"Purpose: Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare, benign vasoproliferative skin disorder. The overall efficacy of current treatments remains suboptimal with frequent recurrence. Recent studies have suggested the type-2 inflammation features of ALHE and emphasized the role of T cells, which calls for further validation.Material and methods: We describe two patients with ALHE, a 65-year-old man and a 27-year-old woman, treated with dupilumab, an IL-4 receptor α-antagonist that has been widely used in chronic skin diseases associated with type 2 inflammation.Results: Both patients achieved sustained responses to dupilumab with favorable safety profiles. The 65-year-old man showed significant improvement after 2 months of treatment, and discontinued treatment after 12 cycles. No relapse was observed during a 3-month follow-up. The 27-year-old woman showed reduced nodules on the forehead after 4 cycles of treatment and continued the treatment at 300 mg per month for 7 months without relapse.Conclusions: These cases support the type 2 inflammation features of ALHE and underscore the critical role of T cells in the pathogenesis. Moreover, these cases also highlight the promising use of dupilumab or other T-helper cell type 2-mediating therapies in treating ALHE.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2485262"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychosocial interventions for psoriasis: a Bayesian network meta-analysis. 社会心理干预治疗牛皮癣：贝叶斯网络荟萃分析。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-05-07 DOI: 10.1080/09546634.2024.2427321

Lingling Lu, Yujuan Xu, Meiling Shi, Aimin Liu

{"title":"Psychosocial interventions for psoriasis: a Bayesian network meta-analysis.","authors":"Lingling Lu, Yujuan Xu, Meiling Shi, Aimin Liu","doi":"10.1080/09546634.2024.2427321","DOIUrl":"10.1080/09546634.2024.2427321","url":null,"abstract":"Background: Psoriasis impacts patients' mental and physical health, prompting interest in psychosocial interventions.Aim: To compare and rank different psychosocial interventions for psoriasis and their effects on well-being and mental health.Methods: A systematic search was conducted using Cochrane Library, EMBASE, Medline, and PsycINFO (via the OVID) from their inception to 6 February 2024. Trials investing in psychosocial therapy in psoriasis patients were included using A random-effects network meta-analysis (NMW) within a Bayesian framework focusing on dermatology life quality index (DLQI), depression, and anxiety, along with adherence to treatment. The risk of bias was assessed by the Cochrane Handbook.Results: Thirteen studies with 6 treatments and 1233 patients were included. The quality of the included studies was low. For DLQI, 9 studies were eligible, mindfulness + treatment as usual (TAU) was better than TAU (MD = -7.21, 95%CI [-14.89, 0.54]). Cognitive behavioral therapy (CBT) + TAU were more effective in improving HADS-anxiety (MD = -2.17, 95%CI [-3.86, -0.49]) and HADS-depression (MD = -1.58, 95%CI [-3.65, 0.68]). Regarding adherence, CBT + TAU (MD = 0.84, 95%CI [-0.62, 2.27]) ranked first, followed by motivational interviewing + TAU.Conclusion: We confirmed the effectiveness of psychosocial interventions on patients' well-being and mental health and recommended several interventions for clinical practice. However, the results should be cautiously interpreted, due to lacking high-quality and more replication studies.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2427321"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corticosteroid-induced skin damage improved with pimecrolimus cream 1% treatment: a 1-year study in adults with mild to moderate atopic dermatitis. 吡美莫司乳膏1%治疗可改善皮质类固醇引起的皮肤损伤：一项针对轻度至中度特应性皮炎成人的1年研究。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-20 DOI: 10.1080/09546634.2025.2493931

Diamant Thaçi, Matthias Bräutigam, Thomas Luger

{"title":"Corticosteroid-induced skin damage improved with pimecrolimus cream 1% treatment: a 1-year study in adults with mild to moderate atopic dermatitis.","authors":"Diamant Thaçi, Matthias Bräutigam, Thomas Luger","doi":"10.1080/09546634.2025.2493931","DOIUrl":"10.1080/09546634.2025.2493931","url":null,"abstract":"Background and objectives: Long-term treatment with topical corticosteroids (TCS) can lead to skin atrophy and telangiectasia at the application site. The objective of this study was to investigate if reversal of TCS-induced skin damage in patients with atopic dermatitis (AD) can be achieved by treatment with pimecrolimus cream 1%, especially in sensitive skin areas like the face.Methods: Forty-one adult patients with mild to moderate atopic dermatitis and preexisting moderate TCS-induced skin damage on the face and cubital areas were intermittently treated for 48-52 weeks with pimecrolimus cream 1%. Skin atrophy and telangiectasia were evaluated by a dermatoscope connected to a digital camera (Dermatophot). In 11 patients skin thickness was measured by ultrasound.Results: Compared with baseline, the Dermatophot score improved by 30.5% (p < .0001; 95% CI: 20.8%-40.1%) on the face and by 38.6% (p < .0001; 95% CI: 28.2%-49.0%) on the cubital areas. In parallel, skin thickness increased by 64.4% (p = .002) on the face and by 19.9% (p = .016) on the cubital areas. During the study clinical symptoms improved in almost 60% of the patients.Conclusion: Reversal of TCS-induced skin atrophy/telangiectasia was observed in approximately 1/2 of patients using chronic intermittent treatment with pimecrolimus cream 1%.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2493931"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0